TGFB2 and cancer: Blockade of TGF-β2 signaling reduced plasma membrane-associated CD36 expression (Fig. 4g) and using a fluorescent palmitate analog (BODIPY-conjugated C16), we confirmed the increased capacity of FA uptake by TGFβ2-stimulated native cancer cells (Supplementary Fig. 4c).